Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Start-Up Seals Deal For Harvard's Tissue Repair Tech

Executive Summary

HoliStick Medical has gained a worldwide exclusive license from Harvard University for a catheter-based tool to repair tissue defects in difficult-to-reach organs.  

You may also be interested in...



Truffle Capital Raises €250M For New BioMedtech VC Fund

French VC firm Truffle Capital has raised €250 million ($278m) for its new BioMedTech fund. The capital will be used to create 12 new medtech companies.

Truffle Eyes A Dozen Investments With New BioMedtech Fund

Truffle Capital has raised $102m for its new institutional venture fund, nearly half of its $240m target, and is set to create and finance a dozen biotech and medtech companies with the capital.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Topics

Latest News
UsernamePublicRestriction

Register

MT122407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel